IBRX
ImmunityBio, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +19.4% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 26.24K | $260,014 | n/a | n/a |
| Q2 2026 | 105 | +5 | 153.86M | $1.35B | +10 | −5 |
| Q1 2026 | 103 | +11 | 130.83M | $998.92M | +19 | −8 |
| Q4 2025 | 91 | -1 | 143.54M | $283.94M | n/a | −1 |
| Q3 2025 | 15 | 0 | 77.60M | $190.89M | +2 | −2 |
| Q2 2025 | 12 | +1 | 58.35M | $154.05M | +1 | n/a |
| Q1 2025 | 8 | 0 | 12.96M | $39.01M | +1 | −1 |
| Q4 2024 | 8 | +1 | 14.27M | $36.54M | +2 | −1 |
| Q3 2024 | 6 | 0 | 5.93M | $22.06M | +1 | −1 |
| Q2 2024 | 6 | n/a | 4.42M | $27.95M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 27.66M | +26.8% | $68.03M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 19.81M | +11.5% | $48.73M | 0.0% | ▲ Add | 2 | SEC ↗ ×11 |
| 3 | State Street Global Advisors ✦ (passive) | 11.32M | +48.6% | $27.84M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 6.89M | +19.3% | $16.95M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Morgan Stanley ✦ | 3.37M | n/a | $8.30M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 6 | Two Sigma Investments ✦ | 2.61M | +224.9% | $6.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | JPMorgan Chase ✦ | 2.12M | n/a | $5.21M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 8 | Goldman Sachs Group ✦ | 1.14M | n/a | $2.81M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 9 | Citadel Advisors ✦ | 1.13M | +43.8% | $2.78M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Renaissance Technologies ✦ | 1.02M | New | $2.50M | 0.0% | New | 1 | SEC ↗ |
| 11 | Marshall Wace ✦ | 254.81K | New | $626,844 | 0.0% | New | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 121.05K | +5.3% | $298,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 103.78K | -34.8% | $255,296 | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 14 | Millennium Management ✦ | 48.30K | -98.5% | $118,808 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | Fidelity (FMR) ✦ | 10.91K | -22.8% | $26,848 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $2.50M | 0.0% |
| Marshall Wace | $626,844 | 0.0% |
Exited
| D. E. Shaw & Co. | $626,068 | was 0.0% |
| Gotham Asset Management | $42,831 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 383 holders, 176.43M shares, $1.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 25.00K sh · $268,760
Director · 81.06K sh · $851,088
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
24.7% of class · View original SEC filing ↗